Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4209MR)

This product GTTS-WQ4209MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4209MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4196MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ1451MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ7286MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ9671MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ15984MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ14205MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ4276MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ213MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 13C5.5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW